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Angels Dancing on the Tip of a Needle: Interpreting Clinical Trials in
Chronic Obstructive Pulmonary Disease
St. Thomas Aquinas was a distinguished medieval scholar who
successfully reconciled Christian theology with Aristotelian philosophy.
Sadly, he is best known today for the taunts of his critics who likened him
to someone counting the number of angels who could stand on a needle
tip, a metaphor for debating topics of no consequence whenmore urgent
matters need attention. In this issue of the Journal, Han and colleagues
(pp. 1237–1243) conduct a further analysis of the data from the very
large 1-year IMPACT (Informing the Pathway of COPD Treatment)
trial comparing the effectiveness of different inhaled combination
treatments (long-acting antimuscarinic [LAMA]1 long-acting
b2-agonist [LABA] bronchodilators, LABA1 inhaled corticosteroids
[ICS], and LABA1 LAMA1 ICS) given in single inhalers once daily
(1). The primary outcome measure in IMPACT was the rate of
exacerbation, and triple therapy was more effective in exacerbation
prevention than the bronchodilators alone.
Large clinical trials are required because the expected difference
between treatments is small and/or the events of interest are clinically
important but infrequent. Given the time (and expense) of conducting
these investigations, secondary analyses, ideally prespecified before
treatment unblinding, are conducted either to generate new
hypotheses or, as in the case of the paper by Han and colleagues, to
test the robustness of the primary result (1). In an accompanying
editorial, Prof. Suissa, a long-standing critic of many studies of ICS
in chronic obstructive pulmonary disease (COPD), outlines his
concerns about the completeness of the data reporting and
analysis, and the distinguished study authors rebut his assertions in a
second editorial comment. Are they simply counting angels?
The new analysis highlights some important features of the
IMPACT population. Among the 71% using ICS before study
randomization, lung function and health status were rather worse than
ICS-naive subjects, but the reported exacerbation history was similar in
each group. The observed exacerbation rate after randomization was
significantly higher in those taking ICS beforehand, irrespective of the
treatment to which they were randomized. This is in keeping with other
analyses showing that patients taking ICS are more likely to report
exacerbations than those not doing so, irrespective of their prior
exacerbation history (2). It seems that clinicians do identify some
patients who benefit from ICS treatment! Indeed, those taking the least
intense baseline treatment (LAMA alone) showed no benefit from
triple treatment, although whether this reflects their disease severity or
the smaller sample size of this group is unclear. The cumulative event
plots resolve the previous confusion around the misinterpreted time to
first event plots (3) about whether the benefit of triple therapy is
maintained, and this point is further emphasized by the analysis of
data from 30 days after randomization where a positive treatment
signal is still seen in the triple therapy group.
Suissa views the present study as an ICS withdrawal study,
although only 14% of patients had ICS stopped for the study. The
IMPACT patients were sicker than those in either the INSTEAD (4)
or even the WISDOM (Withdrawal of Inhaled Steroids during
Optimal Bronchodilator Management) (5) studies to which he refers,
with over 50% of IMPACT patients having two or more moderate or
severe events and approximately a quarter reporting hospitalization
in the year before randomization. This emphasizes the importance of
understanding which patients have been studied and explains
apparently contradictory results between different trials. Even the
extreme view that the difference in treatments is driven by
exacerbations occurring when ICS treatment is stopped implies that
ICS were doing something useful beforehand. Identifying
appropriate therapy is key to personalized treatment selection, but
the suggestion that prior asthma explains the positive signal seems
optimistic, especially as we have no knowledge of what led to an
initial diagnosis of asthma before it was amended to COPD.
Blood eosinophil count and exacerbation history both predict relapse
when ICS are stopped (6), and the IMPACT group have already
shown how important eosinophil counts can be in a population at
high risk for exacerbation based on their history at study entry (7).
Karl Popper believed that science proceeds by a process
of refutability. Any hypothesis can only be considered correct
until evidence emerges that it cannot adequately explain. By
that standard, the hypothesis that taking ICS in addition to
optimized inhaled bronchodilators in patients meeting the entry
criteria for the IMPACT study seems to be intact. Robust
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and thoughtful challenges like those of Suissa are needed to
ensure that those advocating a treatment have not made significant
errors. On balance, that does not seem to have happened in these
new analyses. Clinicians can be confident that in appropriately
selected patients with COPD with a history of exacerbations
despite taking long-acting inhaled bronchodilators, and especially
in those with blood eosinophilia, regular ICS treatment can reduce the
risk of further moderate and severe events. They should note that
many doctors had worked this out before their patients entered the
IMPACT study and that the results have been very carefully
scrutinized. Surely St. Thomas would have approved. n
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Novel Phenotypes in Respiratory Failure: Same As It Ever Was
A central challenge in clinical studies of acute respiratory
distress syndrome (ARDS) is its inherent heterogeneity (1).
As documented in the landmark LUNG SAFE (Large Observational
Study to Understand the Global Impact of Severe Acute Respiratory
Failure) (2) trial, patients with ARDS present with a spectrum of
abnormalities in gas exchange and respiratory mechanics, a
spectrum of clinical severity, and a spectrum of outcomes. Indeed,
for this reason the Berlin (3) definition of ARDS has been criticized
as being overly broad. A major focus of ARDS clinical research has
therefore been identification of subphenotypes or endotypes
within ARDS that can be used to design trials and tailor treatment.
To date, however, no subphenotype has been demonstrated to
predict treatment response or improve outcomes in a prospective
trial. Crucially, despite its limitations, the Berlin definition does
identify populations of patients that benefit from particular
treatments. Volume- and pressure-limited ventilation, when applied
to the broad population who meet the Berlin definition, reduces
mortality (4). This is likely true even in the setting of relatively
normal respiratory system mechanics. For example, a reanalysis of
ARMA (Ventilation with Lower Tidal Volumes as Compared with
Traditional Tidal Volumes for Acute Lung Injury and the Acute
Respiratory Distress Syndrome) trial data by Hager and colleagues
(5) showed that reduced VT is associated with reduced mortality
even when plateau pressures (Pplats) are not high. In the two
decades since the publication of that landmark trial, initial suspicion
(6) of low VT ventilation has therefore given way to widespread
consensus that most patients with ARDS by the Berlin definition
benefit from a lung-protective approach.
However, we are reminded in the book of Ecclesiastes (Eccles 1:9)
that what has been will be again. The global pandemic due to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought
renewed attention to the phenomenon of respiratory failure with
relatively preserved mechanics and has led some to suggest that
coronavirus disease (COVID-19) respiratory failure, despite nearly
always meeting the Berlin definition (7, 8), is characterized by novel
subtypes of ARDS. Furthermore, it has been asserted that for some
patients with COVID-19 ARDS, deviation from standard lung-
protective settings (in particular, by the use of larger VTs) is
potentially beneficial (9). Advocates point to observations of
preserved respiratory system compliance (Crs) in the setting of
severely impaired gas exchange in COVID-19 as suggestive of a
novel pathophysiology, perhaps related to endothelial dysfunction
and impaired hypoxic vasoconstriction (10). In this issue of the Journal,
however, Panwar and colleagues (pp. 1244–1252) point out that such
phenotypes were easily identifiable the pre–COVID-19 era (11).
The authors undertake reanalysis of data from LUNG SAFE.
They define several categories of Crs impairment and attempt to
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